Natural killer cell engagers for cancer immunotherapy
This review article explores the rapidly evolving field of bi-, tri-, and multi-specific NK cell engagers (NKCEs), highlighting their potential as a cutting-edge approach in cancer immunotherapy. NKCEs offer a significant advancement over conventional monoclonal antibodies (mAbs) by enhancing Antibo...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1483884/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591942639157248 |
|---|---|
| author | Shahryar Khoshtinat Nikkhoi Geng Li Arash Hatefi Arash Hatefi |
| author_facet | Shahryar Khoshtinat Nikkhoi Geng Li Arash Hatefi Arash Hatefi |
| author_sort | Shahryar Khoshtinat Nikkhoi |
| collection | DOAJ |
| description | This review article explores the rapidly evolving field of bi-, tri-, and multi-specific NK cell engagers (NKCEs), highlighting their potential as a cutting-edge approach in cancer immunotherapy. NKCEs offer a significant advancement over conventional monoclonal antibodies (mAbs) by enhancing Antibody-Dependent Cellular Cytotoxicity (ADCC). They achieve this by stably and selectively binding to both NK cell activating receptors and tumor-associated antigens (TAAs). Unlike traditional mAbs, which depend on the relatively transient interaction between their Fc region and CD16a, NKCEs establish more robust connections with a range of activating receptors (e.g., CD16a, NKG2D, NKp30, NKp46, NKG2C) and inhibitory receptors (e.g., Siglec-7) on NK cells, thereby increasing cancer cell killing efficacy and specificity. This review article critically examines the strategies for engineering bi-, tri-, and multi-specific NKCEs for cancer immunotherapy, providing an in-depth analysis of the latest advancements in NKCE platform technologies currently under development by pharmaceutical and biotech companies and discussing the preclinical and clinical progress of these products. While NKCEs show great promise, the review underscores the need for continued research to optimize their therapeutic efficacy and to overcome obstacles related to NK cell functionality in cancer patients. Ultimately, this article presents an overview of the current landscape and future prospects of NKCE-based cancer immunotherapy, emphasizing its potential to revolutionize cancer treatment. |
| format | Article |
| id | doaj-art-e81c3652217642b99ad0cb9319d5538d |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-e81c3652217642b99ad0cb9319d5538d2025-01-22T05:19:49ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14838841483884Natural killer cell engagers for cancer immunotherapyShahryar Khoshtinat Nikkhoi0Geng Li1Arash Hatefi2Arash Hatefi3Department of Pharmaceutics, Rutgers University, Piscataway, NJ, United StatesDepartment of Pharmaceutics, Rutgers University, Piscataway, NJ, United StatesDepartment of Pharmaceutics, Rutgers University, Piscataway, NJ, United StatesCancer Pharmacology Program, Cancer Institute of New Jersey, New Brunswick, NJ, United StatesThis review article explores the rapidly evolving field of bi-, tri-, and multi-specific NK cell engagers (NKCEs), highlighting their potential as a cutting-edge approach in cancer immunotherapy. NKCEs offer a significant advancement over conventional monoclonal antibodies (mAbs) by enhancing Antibody-Dependent Cellular Cytotoxicity (ADCC). They achieve this by stably and selectively binding to both NK cell activating receptors and tumor-associated antigens (TAAs). Unlike traditional mAbs, which depend on the relatively transient interaction between their Fc region and CD16a, NKCEs establish more robust connections with a range of activating receptors (e.g., CD16a, NKG2D, NKp30, NKp46, NKG2C) and inhibitory receptors (e.g., Siglec-7) on NK cells, thereby increasing cancer cell killing efficacy and specificity. This review article critically examines the strategies for engineering bi-, tri-, and multi-specific NKCEs for cancer immunotherapy, providing an in-depth analysis of the latest advancements in NKCE platform technologies currently under development by pharmaceutical and biotech companies and discussing the preclinical and clinical progress of these products. While NKCEs show great promise, the review underscores the need for continued research to optimize their therapeutic efficacy and to overcome obstacles related to NK cell functionality in cancer patients. Ultimately, this article presents an overview of the current landscape and future prospects of NKCE-based cancer immunotherapy, emphasizing its potential to revolutionize cancer treatment.https://www.frontiersin.org/articles/10.3389/fonc.2024.1483884/fullNKCE platform technologiesNK activating receptorsbispecific trispecific multispecific antibodiesCD16a NKG2D NKG2C NKp30 NKp46cancer immunotherapynatural killer cells (NK cells) |
| spellingShingle | Shahryar Khoshtinat Nikkhoi Geng Li Arash Hatefi Arash Hatefi Natural killer cell engagers for cancer immunotherapy Frontiers in Oncology NKCE platform technologies NK activating receptors bispecific trispecific multispecific antibodies CD16a NKG2D NKG2C NKp30 NKp46 cancer immunotherapy natural killer cells (NK cells) |
| title | Natural killer cell engagers for cancer immunotherapy |
| title_full | Natural killer cell engagers for cancer immunotherapy |
| title_fullStr | Natural killer cell engagers for cancer immunotherapy |
| title_full_unstemmed | Natural killer cell engagers for cancer immunotherapy |
| title_short | Natural killer cell engagers for cancer immunotherapy |
| title_sort | natural killer cell engagers for cancer immunotherapy |
| topic | NKCE platform technologies NK activating receptors bispecific trispecific multispecific antibodies CD16a NKG2D NKG2C NKp30 NKp46 cancer immunotherapy natural killer cells (NK cells) |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1483884/full |
| work_keys_str_mv | AT shahryarkhoshtinatnikkhoi naturalkillercellengagersforcancerimmunotherapy AT gengli naturalkillercellengagersforcancerimmunotherapy AT arashhatefi naturalkillercellengagersforcancerimmunotherapy AT arashhatefi naturalkillercellengagersforcancerimmunotherapy |